Within-Patient Atazanavir Trough Concentration Monitoring in HIV-1-Infected Patients
作者： Rustin D. Crutchley , Qing Ma , Adel Sulaiman , Jill Hochreitter , Gene D. Morse
关键词:
摘要: Objective: Protease inhibitors (PIs) exhibit considerable interpatient pharmacokinetic variability in plasma trough concentrations. Therapeutic drug monitoring (TDM) is occasionally used to guide chronic dosing achieve target concentrations, but its clinical success assumes minimal intrasubject variability. Therefore, our primary objective was evaluate intrapatient atazanavir (ATV) concentrations HIV-1-infected patients. Design/Methods: In a single-site, prospective, cohort study, patients on with or without ritonavir (ATV/r ATV) for 2 clinic visits were enrolled. Adherence and time since last dose (TSLD) verified at each visit. ATV assayed high-performance liquid chromatography. Intra- variation evaluated using the median intraindividual percentage coefficient of (ICV). Results: The mean 24-hour first second visit ATV/r group (n = 10) 598 (CV 84%) 5...
sagepub.com
sci-hub.se 参考文章(23)
Thomas Lang, Kathrin Klein, Joachim Fischer, Andreas Nussler, Peter Neuhaus, Ute Hofmann, Michel Eichelbaum, Matthias Schwab, Ulrich Zanger, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. ,vol. 11, pp. 399- 415 ,(2001) , 10.1097/00008571-200107000-00004
R. E. Nettles, T. L. Kieffer, T. Parsons, J. Johnson, J. Cofrancesco, J. E. Gallant, K. A. Carson, R. F. Siliciano, C. Flexner, Marked Intraindividual Variability in Antiretroviral Concentrations May Limit the Utility of Therapeutic Drug Monitoring Clinical Infectious Diseases. ,vol. 42, pp. 1189- 1196 ,(2006) , 10.1086/501458
S MOULY, C MATHENY, M PAINE, G SMITH, J LAMBA, V LAMBA, S PUSEK, E SCHUETZ, P STEWART, P WATKINS, Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clinical Pharmacology & Therapeutics. ,vol. 78, pp. 605- 618 ,(2005) , 10.1016/J.CLPT.2005.08.014
Esteban Ribera, Carlos Azuaje, Rosa M Lopez, Marjorie Diaz, Maria Feijoo, Leonor Pou, Manuel Crespo, Adria Curran, Imma Ocaña, Albert Pahissa, Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS. ,vol. 20, pp. 1131- 1139 ,(2006) , 10.1097/01.AIDS.0000226953.56976.AD
Ana Barrios, Ana Lucía Rendón, Oscar Gallego, Luz Martín-Carbonero, Luisa Valer, Pilar Ríos, Ivana Maida, Teresa García-Benayas, Inmaculada Jiménez-Nácher, Juan González-Lahoz, Vincent Soriano, Predictors of virological response to atazanavir in protease inhibitor-experienced patients. Hiv Clinical Trials. ,vol. 5, pp. 201- 205 ,(2004) , 10.1310/3HL3-HHBD-WKLR-XELL
Judianne Slish, Qing Ma, Barry S Zingman, Richard C Reichman, Margaret A Fischl, Barbara Gripshover, Alan Forrest, Dan Brazeau, Naomi S Boston, Linda Catanzaro, Robin DiFrancesco, Gene D Morse, Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Therapeutic Drug Monitoring. ,vol. 29, pp. 560- 565 ,(2007) , 10.1097/FTD.0B013E31806DB8AE
Lars St??hle, Lars Moberg, Jan-Olof Svensson, Anders S??nnerborg, Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Therapeutic Drug Monitoring. ,vol. 26, pp. 267- 270 ,(2004) , 10.1097/00007691-200406000-00008
Peter L. Anderson, Jatinder Lamba, Christina L. Aquilante, Erin Schuetz, Courtney V. Fletcher, Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. Journal of Acquired Immune Deficiency Syndromes. ,vol. 42, pp. 441- 449 ,(2006) , 10.1097/01.QAI.0000225013.53568.69
Sara Colombo, Thierry Buclin, Matthias Cavassini, Laurent A. Décosterd, Amalio Telenti, Jérôme Biollaz, Chantal Csajka, Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection Antimicrobial Agents and Chemotherapy. ,vol. 50, pp. 3801- 3808 ,(2006) , 10.1128/AAC.00098-06
John E. Ray, Debbie Marriott, Mark T. Bloch, Andrew J. McLachlan, Therapeutic drug monitoring of atazanavir : surveillance of pharmacotherapy in the clinic British Journal of Clinical Pharmacology. ,vol. 60, pp. 291- 299 ,(2005) , 10.1111/J.1365-2125.2005.02413.X